The Centers for Disease Control (CDC) and the National Cancer Institute (NCI) recently published the Cancer Incidence and Mortality Data, a report that features the official federal statistics on rates of cancer incidence among the US population from 2001-2005.
The stats show that Non-Hodgkin Lymphoma (NHL) is the fifth most common cancer to strike adults males, with an incidence rate of 23.0 per 100,000.
The incidence of NHL among adult women is lower, 16.2 per 100,000, but it still rates as the fifth most common cancer to strike women.
Collectively for men and women in the US of all ages and races, NHL’s mortality rate of 7.6 per 100,000 ranks eighth, just behind Leukemias (7.4). Compare this to the mortality rate for lung cancers (54.1), the highest in the report.
Among male and female children age 19 and younger, Leukemias have the highest rate of occurrence (4.2 per 100,000), with Acute Lymphocytic Leukemia being the dominant form. Hodgkin Lymphoma (1.2 per 100,000) has the third highest rate of occurrence, and NHL (1.1), the fourth.
The full report can be seen by clicking here.
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...